BioPharmSignal logoBioPharmSignal

Biotech News

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX)Annexon, Inc.Earnings

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026 Vonaprument Phase 3 GA Program Expanded with Month 15 / 24 Dual Primary

Related news

ANVSAnnovis Bio2026-08-14 12:00 EST

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

NGENNervGen Pharma2026-08-13 11:30 EST

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

TSHATaysha Gene Therapies2026-08-11 20:00 EST

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

VYGRVoyager Therapeutics2026-08-06 20:01 EST

Voyager Reports Second Quarter 2026 Financial and Operating Results

GHRSGH Research2026-08-06 11:00 EST

GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic, and autoimmune diseases. Tanruprubart Tanruprubart is an antibody therapy for Guillain-Barré syndrome. Its European marketing application is under...

Recent company news

ANNXAnnexon, Inc.2026-08-17 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-08-12 10:05 EST

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

ANNXAnnexon, Inc.2026-08-10 20:05 EST

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Stock data

Close
5.13 USD
Market cap
861.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States